250 related articles for article (PubMed ID: 25874629)
1. Removal of transmissible spongiform encephalopathy prion from large volumes of cell culture media supplemented with fetal bovine serum by using hollow fiber anion-exchange membrane chromatography.
Chou ML; Bailey A; Avory T; Tanimoto J; Burnouf T
PLoS One; 2015; 10(4):e0122300. PubMed ID: 25874629
[TBL] [Abstract][Full Text] [Related]
2. Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion.
Kao YC; Bailey A; Samminger B; Tanimoto J; Burnouf T
Cytotherapy; 2016 Jul; 18(7):911-24. PubMed ID: 27260210
[TBL] [Abstract][Full Text] [Related]
3. Preparation of soluble infectious samples from scrapie-infected brain: a new tool to study the clearance of transmissible spongiform encephalopathy agents during plasma fractionation.
Berardi VA; Cardone F; Valanzano A; Lu M; Pocchiari M
Transfusion; 2006 Apr; 46(4):652-8. PubMed ID: 16584444
[TBL] [Abstract][Full Text] [Related]
4. Towards further reduction and replacement of animal bioassays in prion research by cell and protein misfolding cyclic amplification assays.
Boerner S; Wagenführ K; Daus ML; Thomzig A; Beekes M
Lab Anim; 2013 Apr; 47(2):106-15. PubMed ID: 23479773
[TBL] [Abstract][Full Text] [Related]
5. Bovine colostrum ultrafiltrate supplemented with adult bovine serum and transferrin: an effective FBS substitute for cultivation of Vero and CHO-K1 cells.
Pakkanen R
In Vitro Cell Dev Biol Anim; 1994 May; 30A(5):295-9. PubMed ID: 8069454
[TBL] [Abstract][Full Text] [Related]
6. Prion encephalopathies of animals and humans.
Prusiner SB
Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
[TBL] [Abstract][Full Text] [Related]
7. Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans.
Race R; Raines A; Raymond GJ; Caughey B; Chesebro B
J Virol; 2001 Nov; 75(21):10106-12. PubMed ID: 11581378
[TBL] [Abstract][Full Text] [Related]
8. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products.
Foster PR; Welch AG; McLean C; Griffin BD; Hardy JC; Bartley A; MacDonald S; Bailey AC
Vox Sang; 2000; 78(2):86-95. PubMed ID: 10765143
[TBL] [Abstract][Full Text] [Related]
9. Non-genetic propagation of strain-specific properties of scrapie prion protein.
Bessen RA; Kocisko DA; Raymond GJ; Nandan S; Lansbury PT; Caughey B
Nature; 1995 Jun; 375(6533):698-700. PubMed ID: 7791905
[TBL] [Abstract][Full Text] [Related]
10. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of depth filtration to remove prion challenge from an immune globulin preparation.
Van Holten RW; Autenrieth SM
Vox Sang; 2003 Jul; 85(1):20-4. PubMed ID: 12823726
[TBL] [Abstract][Full Text] [Related]
12. Molecular biology and genetics of prion diseases.
Prusiner SB
Philos Trans R Soc Lond B Biol Sci; 1994 Mar; 343(1306):447-63. PubMed ID: 7913765
[TBL] [Abstract][Full Text] [Related]
13. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate.
Diez JM; Caballero S; Belda FJ; Otegui M; Gajardo R; Jorquera JI
Haemophilia; 2009 Nov; 15(6):1249-57. PubMed ID: 19563480
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie.
Demaimay R; Adjou K; Lasmézas C; Lazarini F; Cherifi K; Seman M; Deslys JP; Dormont D
J Gen Virol; 1994 Sep; 75 ( Pt 9)():2499-503. PubMed ID: 7915757
[TBL] [Abstract][Full Text] [Related]
15. Rapid assessment of bovine spongiform encephalopathy prion inactivation by heat treatment in yellow grease produced in the industrial manufacturing process of meat and bone meals.
Yoshioka M; Matsuura Y; Okada H; Shimozaki N; Yamamura T; Murayama Y; Yokoyama T; Mohri S
BMC Vet Res; 2013 Jul; 9():134. PubMed ID: 23835086
[TBL] [Abstract][Full Text] [Related]
16. Prion inactivation by the Maillard reaction.
Suyama K; Yoshioka M; Akagawa M; Murayama Y; Horii H; Takata M; Yokoyama T; Mohri S
Biochem Biophys Res Commun; 2007 Apr; 356(1):245-8. PubMed ID: 17336934
[TBL] [Abstract][Full Text] [Related]
17. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
[TBL] [Abstract][Full Text] [Related]
18. Prion protein and the transmissible spongiform encephalopathy diseases.
Chesebro B
Neuron; 1999 Nov; 24(3):503-6. PubMed ID: 10595502
[No Abstract] [Full Text] [Related]
19. Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates.
Sowemimo-Coker SO; Pesci S; Andrade F; Kim A; Kascsak RB; Kascsak RJ; Meeker C; Carp R
Vox Sang; 2006 May; 90(4):265-75. PubMed ID: 16635068
[TBL] [Abstract][Full Text] [Related]
20. Transmissibility of H-Type Bovine Spongiform Encephalopathy to Hamster PrP Transgenic Mice.
Okada H; Masujin K; Miyazawa K; Yokoyama T
PLoS One; 2015; 10(10):e0138977. PubMed ID: 26466381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
